The global biotech industry is booming, and by 2025 it will reach an estimated market worth of $729B. But while great innovation is driven by emerging biotechs, these companies often lack resources, infrastructure, and network to climb the slope of drug development alone.
We put together these guidelines to help early-stage biotechs navigate the stages of drug development and tackle the most difficult decisions upfront. You will learn how to build a solid strategy, find the right partners, mitigate risk, outsource the right way (via CRO, CMO or CDMO), and understand upstream process development & manufacturing.
"*" indicates required fields